IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
Antibiotics · 27.02.2026 · 15 (3) · 251
DOI: 10.3390/antibiotics15030251 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 27.02.2026. Verfasst von Jelena Šuran und 6 weiteren Autor:innen. Beteiligte Einrichtung: Apiotix Technologies d.o.o., Hrvojeva 12, 21000 Split, Croatia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO) share symptoms such as abdominal pain, bloating, and altered bowel habits. Both are linked to dysbiosis and gut–brain axis dysfunction. IBS is a multifactorial disorder characterized by abnormal motility, visceral hypersensitivity, low-grade inflammation, and alterations in the microbiota. In contrast, SIBO is defined by excessive bacterial colonization of the small intestine that can mimic or worsen IBS symptoms. Gut microbes and their metabolites influence motility, immune activation, barrier integrity, and gas production; methanogen overgrowth is associated with constipation-predominant presentations, while hydrogen- and hydrogen sulfide-related pathways may contribute to diarrhea and bloating. Because recurrent or empiric antibiotic use is common—particularly in suspected SIBO—yet carries risks of resistance, microbiome disruption, and relapse, there is a strong rationale to prioritize effective non-antibiotic strategies. Accordingly, this review synthesizes current evidence on IBS/SIBO pathophysiology and microbiota interactions. It evaluates non-pharmacological interventions including dietary approaches, probiotics/prebiotics, herbal therapies, and mind–body treatments (e.g., cognitive behavioral therapy and gut-directed hypnotherapy). We emphasize an integrative framework that supports symptom control and quality of life while helping reduce unnecessary antibiotic exposure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Apiotix Technologies d.o.o., Hrvojeva 12, 21000 Split, Croatia.
- Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia.
- Laboratory for Cardiometabolic Research, University of Split School of Medicine, 21000 Split, Croatia.
- Department of Cardiovascular Diseases, University Hospital of Split, 21000 Split, Croatia.
- Department of Anatomy, Histology and Embryology, University of Split School of Medicine, 21000 Split, Croatia.
- Mediterranean Institute for Life Sciences, University of Split, 21000 Split, Croatia.
ORCID-Profile: Nikola Pavlović, Joško Božić, Marko Kumrić, Katarina Vukojević, Natalija Filipović, Božo Radić
Zitieren
APA
Šuran, J., Pavlović, N., Božić, J., Kumrić, M., Vukojević, K., Filipović, N., & Radić, B. (2026). IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions. Antibiotics, 15(3), 251. https://doi.org/10.3390/antibiotics15030251
Vancouver
Šuran J, Pavlović N, Božić J, Kumrić M, Vukojević K, Filipović N, et al. IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions. Antibiotics. 2026;15(3):251. doi:10.3390/antibiotics15030251
BibTeX
@article{uran2026,
author = {Šuran, Jelena and Pavlović, Nikola and Božić, Joško and Kumrić, Marko and Vukojević, Katarina and Filipović, Natalija and Radić, Božo},
title = {IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {3},
pages = {251},
doi = {10.3390/antibiotics15030251}
}
EUVIMED